explore -WSS

explore

author：explore 2025-09-30 00:45:00 - browse：6649

Colorful illustration of scientists using computers and Artificial Intelligence technology to visualize proteins for drug development – biotech coverage from STAT — Mike Reddy for STAT

David Reese calls it a “hinge moment” — the turning point when biotech and big tech merge to attack human disease with artificial intelligence.

At Amgen, where he’s led drug research and development since 2018, Reese said this moment has finally arrived. The proof lies not only in organizational changes, such as his recent appointment as the company’s first chief technology officer, but also in Amgen’s broader push to embed AI into every aspect of the drug discovery process.

“We’re now seeing 10-fold improvements in these (AI) models every six months,” said Reese, a medical oncologist by training. He added that the quickening pace of advancement means investing in the technology is no longer optional: “It’s something we must do to have a practical, pragmatic impact on drug discovery.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Biotech stock slump in 2023: awaiting the turnaround

focus

WSS

Emergency workers more likely to restrain Black patients: study

Bird flu outbreak in cows is latest avian flu curveball

Bird flu outbreak in cows is latest avian flu curveball

Senate HELP committee spars over health care workforce policies

CommonSpirit Health keeps growing, even as it loses money

Senators: Long

entertainment

explore

knowledge

Medicare details structure of new drug price negotiation program

Orangutan used medicinal plant to treat wound, first time ever seen

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Dogs on Prozac: What pet anti

Walensky prepares to leave CDC — and Congress — behind

Bird flu outbreak in cows is latest avian flu curveball

BioMarin wins approval for gene therapy to treat hemophilia A

Q&A: Jennifer Adair on making gene therapy available globally

The high cost of giving birth even with insurance

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

knowledge

Drug for rare kidney disease narrowly misses mark in clinical trial

FDA panel to weigh approval of NurOwn, controversial ALS drug

STAT Virtual Event: Putting AI to the Test

Medical bills so high, Medicare adding extra digits to claim forms

MassMutual is introducing free genetic testing for members

Exact Sciences stock tumbles despite strong cancer detection sales

leisure time

focus

focus

hotspot